BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38252906)

  • 1. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
    Crombie JL; Graff T; Falchi L; Karimi YH; Bannerji R; Nastoupil L; Thieblemont C; Ursu R; Bartlett N; Nachar V; Weiss J; Osterson J; Patel K; Brody J; Abramson JS; Lunning M; Shah NN; Ayed A; Kamdar M; Parsons B; Caimi P; Flinn I; Herrera A; Sharman J; McKenna M; Armand P; Kahl B; Smith S; Zelenetz A; Budde LE; Hutchings M; Phillips T; Dickinson M
    Blood; 2024 Apr; 143(16):1565-1575. PubMed ID: 38252906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
    Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
    EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
    Trabolsi A; Arumov A; Schatz JH
    Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
    Mohan M; Chakraborty R; Bal S; Nellore A; Baljevic M; D'Souza A; Pappas PG; Berdeja JG; Callander N; Costa LJ
    Br J Haematol; 2023 Dec; 203(5):736-746. PubMed ID: 37287117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific Antibodies in the Treatment of Multiple Myeloma.
    Zhou X; Xiao X; Kortuem KM; Einsele H
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):361-381. PubMed ID: 38199897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
    Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies in haematological malignancies.
    Viardot A; Bargou R
    Cancer Treat Rev; 2018 Apr; 65():87-95. PubMed ID: 29635163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
    Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
    Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.
    Park JA; Santich BH; Xu H; Lum LG; Cheung NV
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
    Ludwig H; Terpos E; van de Donk N; Mateos MV; Moreau P; Dimopoulos MA; Delforge M; Rodriguez-Otero P; San-Miguel J; Yong K; Gay F; Einsele H; Mina R; Caers J; Driessen C; Musto P; Zweegman S; Engelhardt M; Cook G; Weisel K; Broijl A; Beksac M; Bila J; Schjesvold F; Cavo M; Hajek R; Touzeau C; Boccadoro M; Sonneveld P
    Lancet Oncol; 2023 Jun; 24(6):e255-e269. PubMed ID: 37269857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
    Kazandjian D; Kowalski A; Landgren O
    Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.
    Markouli M; Ullah F; Unlu S; Omar N; Lopetegui-Lia N; Duco M; Anwer F; Raza S; Dima D
    Curr Oncol; 2023 Jul; 30(7):6330-6352. PubMed ID: 37504327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.
    Holstein SA; Grant SJ; Wildes TM
    J Clin Oncol; 2023 Sep; 41(27):4416-4429. PubMed ID: 37471687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas.
    Salvaris R; Ong J; Gregory GP
    J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33946635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating Immune Therapies for the Treatment of Multiple Myeloma.
    Mikkilineni L; Sidana S
    J Natl Compr Canc Netw; 2023 Dec; 21(12):1303-1311. PubMed ID: 38081142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas.
    Major A; Kamdar M
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):370-381. PubMed ID: 38066907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
    Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.